329 related articles for article (PubMed ID: 24801917)
1. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus.
Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Takahashi T; Toyama T; Ichimura Y; Noda S; Akamata K; Miyazaki M; Kuwano Y; Yanaba K; Sato S
J Dermatol; 2014 May; 41(5):418-20. PubMed ID: 24801917
[TBL] [Abstract][Full Text] [Related]
2. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
3. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
4. A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies.
Cavazzana I; Fredi M; Taraborelli M; Quinzanini M; Tincani A; Franceschini F
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):118-21. PubMed ID: 23910615
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Simon D; Czömpöly T; Berki T; Minier T; Peti A; Tóth E; Czirják L; Németh P
Int Immunol; 2009 Apr; 21(4):415-22. PubMed ID: 19211583
[TBL] [Abstract][Full Text] [Related]
6. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
7. Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
Richter P; Cardoneanu A; Dima N; Bratoiu I; Rezus C; Burlui AM; Costin D; Macovei LA; Rezus E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298342
[TBL] [Abstract][Full Text] [Related]
8. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
9. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.
Lopez LR; Simpson DF; Hurley BL; Matsuura E
Ann N Y Acad Sci; 2005 Jun; 1051():313-22. PubMed ID: 16126973
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
[TBL] [Abstract][Full Text] [Related]
11. Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes.
Chauhan R; Handa R; Das TP; Pati U
Clin Exp Immunol; 2004 Jun; 136(3):574-84. PubMed ID: 15147363
[TBL] [Abstract][Full Text] [Related]
12. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
Russo K; Hoch S; Dima C; Varga J; Teodorescu M
J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
15. Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus.
Moazedi-Fuerst FC; Kielhauser S; Brickmann K; Tripolt N; Meilinger M; Lufti A; Graninger W
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S87-91. PubMed ID: 25665185
[TBL] [Abstract][Full Text] [Related]
16. Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody.
Katsumi S; Kobayashi N; Yamamoto Y; Miyagawa S; Shirai T
Br J Dermatol; 2000 May; 142(5):1030-3. PubMed ID: 10809868
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
[TBL] [Abstract][Full Text] [Related]
19. Treatment of SLE with anti-CD20 monoclonal antibody.
Looney RJ; Anolik J; Sanz I
Curr Dir Autoimmun; 2005; 8():193-205. PubMed ID: 15564722
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
